The company plans to import the listed controlled substance in bulk for manufacture of analytical reference material which, in its final form, is an exempted product.

Dated: July 15, 2019.

#### John J. Martin,

Assistant Administrator.

[FR Doc. 2019–15738 Filed 7–23–19; 8:45 am]

BILLING CODE 4410-09-P

## **DEPARTMENT OF JUSTICE**

#### **Drug Enforcement Administration**

[Docket No. DEA-392]

Importer of Controlled Substances Application: AMRI Rensselaer, Inc.

**ACTION:** Notice of application.

**DATES:** Registered bulk manufacturers of the affected basic classes, and applicants therefore, may file written comments on or objections to the issuance of the proposed registration on or before August 23, 2019. Such persons may also file a written request for a hearing on the application on or before August 23, 2019.

ADDRESSES: Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, Springfield, Virginia 22152. All requests for a hearing must be sent to: Drug Enforcement Administration, Attn: Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152. All requests for a hearing should also be sent to: (1) Drug Enforcement Administration, Attn: Hearing Clerk/OALJ, 8701 Morrissette Drive, Springfield, Virginia 22152; and (2) Drug Enforcement Administration, Attn: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, Springfield, Virginia 22152.

# SUPPLEMENTARY INFORMATION:

In accordance with 21 CFR 1301.34(a), this is notice that on May 7, 2019, AMRI Rensselaer, Inc., 33 Riverside Avenue, Rensselaer, New York 12144 applied to be registered as an importer of the following basic class of controlled substance:

Controlled sub- stance	Drug code	Schedule
Poppy Straw Concentrate.	9670	II

The company plans to import the listed controlled substance to manufacture a bulk controlled substance for distribution to its customers.

Dated: July 15, 2019.

#### John J. Martin,

Assistant Administrator.

[FR Doc. 2019–15737 Filed 7–23–19; 8:45 am]

BILLING CODE 4410-09-P

## **DEPARTMENT OF JUSTICE**

[Docket No. DEA-392]

Drug Enforcement Administration Bulk Manufacturer of Controlled Substances Application: IsoSciences, LLC

**ACTION:** Notice of application.

**DATES:** Registered bulk manufacturers of the affected basic classes, and applicants therefore, may file written comments on or objections to the issuance of the proposed registration on or before September 23, 2019.

ADDRESSES: Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, Springfield, Virginia 22152.

#### SUPPLEMENTARY INFORMATION:

In accordance with 21 CFR 1301.33(a), this is notice that on May 21, 2019, IsoSciences, LLC, 340 Mathers Road, Ambler, Pennsylvania 19002– 3420 applied to be registered as a bulk manufacturer of the following basic classes of controlled substances:

Controlled substance		Schedule
Cathinone	1235	1
Methcathinone	1237	1
_ysergic acid diethylamide	7315	1
Marihuana	7360	1
Tetrahydrocannabinols	7370	1
3,4-Methylenedioxyamphetamine	7400	1
3,4-Methylenedioxy-N-ethylamphetamine	7404	1
3,4-Methylenedioxymethamphetamine	7405	1
5-Methoxy-N-N-dimethyltryptamine	7431	1
Alpha-methyltryptamine	7432	1
Bufotenine	7433	1
Diethyltryptamine	7434	1
Dimethyltryptamine	7435	1
Psilocybin	7437	1
Psilocyn	7438	1
5-Methoxy-N,N-diisopropyltryptamine	7439	1
Dihydromorphine	9145	li
Heroin	9200	1
Vicocodeine	9309	l i
Vicomorphine	9312	l i
Normorphine	9313	li
Thebacon	9315	li
Normethadone	9635	l i
Acryl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylacrylamide)	9811	li
Para-Fluorofentanyl	9812	li
l-Methylfentanyl	9813	li
Alpha-methylfentanyl	9814	l i
Acetyl-alpha-methylfentanyl	9815	l i
N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)propionamide	9816	li
Acetyl Fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide)	9821	li
Butyryl Fentanyl	9822	Li

Controlled substance		Schedule
4-Fluoroisobutyryl fentanyl (N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide)	9824	1
2-methoxy-N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide	9825	1
Beta-hydroxyfentanyl	9830	1
Beta-hydroxy-3-methylfentanyl	9831	1
Alpha-methylthiofentanyl	9832	1
3-Methylthiofentanyl	9833	1
Furanyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylfuran-2-carboxamide)	9834	1
Thiofentanyl	9835	1
Beta-hydroxythiofentanyl	9836	1
N-(1-phenethylpiperidin-4-yl)-N-phenyltetrahydrofuran-2-carboxamide	9843	1
Amphetamine	1100	II
Methamphetamine	1105	II
Codeine	9050	II
Dihydrocodeine	9120	II
Oxycodone	9143	II
Hydromorphone	9150	II
Hydrocodone	9193	II
Isomethadone	9226	II
Methadone	9250	II
Methadone intermediate	9254	II
Morphine	9300	II
Thebaine	9333	II
Levo-alphacetylmethadol	9648	II
Oxymorphone	9652	II
Thiafentanil	9729	II
Alfentanil	9737	II
Sufentanil	9740	II
Carfentanil	9743	II
Fentanyl	9801	II

The company plans to manufacture bulk controlled substances for use in analytical testing. In reference to drug codes 7360 (marihuana) and 7370 (THC), the company plans to bulk manufacture these drugs as synthetics. No other activities for these drug codes are authorized for this registration.

Dated: July 11, 2019.

## John J. Martin,

Assistant Administrator.

[FR Doc. 2019–15739 Filed 7–23–19; 8:45 am]

BILLING CODE 4410-09-P

### **LEGAL SERVICES CORPORATION**

## **Sunshine Act Meeting**

TIME AND DATE: The Legal Services Corporation's Board of Directors and its six committees will meet July 28-30, 2019. On Sunday, July 28, the first meeting will commence at 12:30 p.m., Eastern Daylight Time (EDT), with the meetings thereafter commencing promptly upon adjournment of the immediately preceding meeting. On Monday, July 29, the first meeting will commence at 9:30 a.m. (EDT), with the next meeting commencing promptly upon adjournment of the immediately preceding meeting. The closed session meeting of the Board of Directors will commence promptly upon adjournment of the open session of the Board of Directors meeting.

**PLACE:** The Courtyard by Marriott Portland, Downtown Waterfront, 321 Commercial Street, Portland, Maine 04101.

**STATUS:** Unless otherwise noted herein, the Board and all committee meetings will be open to public observation. Members of the public who are unable to attend in person but wish to listen to the public proceedings may do so by following the telephone call-in directions provided below.

Call-in Directions for Open Sessions:

- Call toll-free number: 1–866–451–4981:
- When prompted, enter the following numeric pass code: 5907707348.
- Once connected to the call, your telephone line will be *automatically* "MUTED".
- To participate in the meeting during public comment press #6 to "UNMUTE" your telephone line, once you have concluded your comments please press \*6 to "MUTE" your line.

Members of the public are asked to keep their telephones muted to eliminate background noises. To avoid disrupting the meeting, please refrain from placing the call on hold if doing so will trigger recorded music or other sound. From time to time, the presiding Chair may solicit comments from the public.

#### **Meeting Schedule**

Sunday, July 28, 2019: Time: \* 12:30 p.m.

- 1. Operations & Regulations Committee
- 2. Governance and Performance Review Committee
- 3. Communications Subcommittee Committee
- 4. Institutional Advancement Committee

Monday, July 29, 2019: 9:30 a.m.

- 1. Audit Committee
- 2. Delivery of Legal Services Committee

Tuesday, July 30, 2019: 8:00 a.m.

- 1. Finance Committee
- 2. Board of Directors

Status of Meeting: Open, except as noted below.

Board of Directors—Open, except that, upon a vote of the Board of Directors, a portion of the meeting may be closed to the public to hear briefings by management and LSC's Inspector General, and to consider and act on the General Counsel's report on potential and pending litigation involving LSC, and on a list of prospective funders.\*\*

Continued

<sup>\*</sup> Please note that all times in this notice are in Eastern Daylight Time.

<sup>\*\*</sup> Any portion of the closed session consisting solely of briefings does not fall within the Sunshine Act's definition of the term "meeting" and, therefore, the requirements of the Sunshine Act do not apply to such portion of the closed session. 5